CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy
| Autor: | Victoria M. Richon, Wm. Kevin Kelly, Paul A. Marks |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty medicine.drug_class business.industry Histone deacetylase inhibitor Pharmacology Hydroxamic Acids Histone Deacetylase Inhibitors Hematologic Neoplasms Internal medicine medicine Humans Female business Vorinostat Epigenetic therapy medicine.drug |
| Zdroj: | Clinical Cancer Research. 21:2198-2200 |
| ISSN: | 1557-3265 1078-0432 |
| DOI: | 10.1158/1078-0432.ccr-14-2556 |
| Popis: | The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenously. Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors. Clin Cancer Res; 21(10); 2198–200. ©2015 AACR. See related article by Kelly et al., Clin Cancer Res 2003;9(10) September 1, 2003;3578–88 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|